Search research articles
Contact Us
Filters
Showing results (221-230 of 260) with videos related to
Page
of 26
Sort By:
Cancer Discovery
|
June 14, 2025
Phase Ib basket expansion trial and alternative-schedule dose-escalation study of ATR inhibitor elimusertib in advanced solid tumors with DNA damage response defects
Timothy A Yap, David S P Tan, Anastasios Stathis, et al.
The Oncologist
|
April 24, 2025
Barriers to publishing early phase clinical trials: the oncologists' perspective
Merel J J Lucassen, Pedro Bergmann, Olga Husson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 21, 2014
Interrogating two schedules of the AKT inhibitor MK-2206 in patients with advanced solid tumors incorporating novel pharmacodynamic and functional imaging biomarkers
Timothy A Yap, Li Yan, Amita Patnaik, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 22, 2021
First-In-Human Phase I Study of a Next-Generation, Oral, TGFβ Receptor 1 Inhibitor, LY3200882, in Patients with Advanced Cancer
Timothy A Yap, Maria Vieito, Capucine Baldini, et al.
Molecular Cancer Therapeutics
|
April 1, 2024
Loss of the DNA Repair Gene RNase H2 Identifies a Unique Subset of DDR-Deficient Leiomyosarcomas
Michael S Nakazawa, Ian M Silverman, Victoria Rimkunas, et al.
NPJ Precision Oncology
|
October 27, 2022
Challenges and opportunities associated with the MD Anderson IMPACT2 randomized study in precision oncology
Henry Hiep Vo, Siqing Fu, David S Hong, et al.
Nature Communications
|
February 3, 2025
Early tolerance and late persistence as alternative drug responses in cancer
Simona Punzi, Davide Cittaro, Guido Gatti, et al.
Cancer Discovery
|
September 29, 2020
First-in-Human Trial of the Oral Ataxia Telangiectasia and RAD3-Related (ATR) Inhibitor BAY 1895344 in Patients with Advanced Solid Tumors
Timothy A Yap, David S P Tan, Angelika Terbuch, et al.
Nature
|
September 5, 2020
Publisher Correction: The National Lung Matrix Trial of personalized therapy in lung cancer
Gary Middleton, Peter Fletcher, Sanjay Popat, et al.
Molecular Cancer Research : MCR
|
December 16, 2020
Molecular Profiling of Metastatic Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient Outcomes
Omar Alhalabi, Andrew W Hahn, Pavlos Msaouel, et al.
Page
of 26
Search research articles
Search
Showing results (221-230 of 260) with videos related to
Sort By:
Page
of 26
Cancer Discovery
|
June 14, 2025
Phase Ib basket expansion trial and alternative-schedule dose-escalation study of ATR inhibitor elimusertib in advanced solid tumors with DNA damage response defects
Timothy A Yap, David S P Tan, Anastasios Stathis, et al.
The Oncologist
|
April 24, 2025
Barriers to publishing early phase clinical trials: the oncologists' perspective
Merel J J Lucassen, Pedro Bergmann, Olga Husson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 21, 2014
Interrogating two schedules of the AKT inhibitor MK-2206 in patients with advanced solid tumors incorporating novel pharmacodynamic and functional imaging biomarkers
Timothy A Yap, Li Yan, Amita Patnaik, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 22, 2021
First-In-Human Phase I Study of a Next-Generation, Oral, TGFβ Receptor 1 Inhibitor, LY3200882, in Patients with Advanced Cancer
Timothy A Yap, Maria Vieito, Capucine Baldini, et al.
Molecular Cancer Therapeutics
|
April 1, 2024
Loss of the DNA Repair Gene RNase H2 Identifies a Unique Subset of DDR-Deficient Leiomyosarcomas
Michael S Nakazawa, Ian M Silverman, Victoria Rimkunas, et al.
NPJ Precision Oncology
|
October 27, 2022
Challenges and opportunities associated with the MD Anderson IMPACT2 randomized study in precision oncology
Henry Hiep Vo, Siqing Fu, David S Hong, et al.
Nature Communications
|
February 3, 2025
Early tolerance and late persistence as alternative drug responses in cancer
Simona Punzi, Davide Cittaro, Guido Gatti, et al.
Cancer Discovery
|
September 29, 2020
First-in-Human Trial of the Oral Ataxia Telangiectasia and RAD3-Related (ATR) Inhibitor BAY 1895344 in Patients with Advanced Solid Tumors
Timothy A Yap, David S P Tan, Angelika Terbuch, et al.
Nature
|
September 5, 2020
Publisher Correction: The National Lung Matrix Trial of personalized therapy in lung cancer
Gary Middleton, Peter Fletcher, Sanjay Popat, et al.
Molecular Cancer Research : MCR
|
December 16, 2020
Molecular Profiling of Metastatic Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient Outcomes
Omar Alhalabi, Andrew W Hahn, Pavlos Msaouel, et al.
Page
of 26